American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
CNS Pharmaceuticals, Inc.
$7.3MMarket cap
-$15.9MNet income
8Employees
CNSPNASDAQ
2019IPO
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Net income
- -$15.9M
- Total assets
- $8.6M
- Market cap
- $7.3M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $7.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 8, 2019
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review CNS Pharmaceuticals, Inc..
Write a review
Explore
Browse all →
